Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 242

1.

Type 2 diabetes mellitus: managing hemoglobin A(1c) and beyond.

Fowler GC, Vasudevan DA.

South Med J. 2010 Sep;103(9):911-6. doi: 10.1097/SMJ.0b013e3181eb34b2. Review.

PMID:
20689486
2.

Control of postprandial glucose levels with insulin in type 2 diabetes.

Blevins T.

Postgrad Med. 2011 Jul;123(4):135-47. doi: 10.3810/pgm.2011.07.2313. Review.

PMID:
21680998
3.
4.
5.

Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels.

Woerle HJ, Neumann C, Zschau S, Tenner S, Irsigler A, Schirra J, Gerich JE, Göke B.

Diabetes Res Clin Pract. 2007 Aug;77(2):280-5. Epub 2007 Jan 22.

PMID:
17240473
7.

Postprandial peaks as a risk factor for cardiovascular disease: epidemiological perspectives.

Bonora E.

Int J Clin Pract Suppl. 2002 Jul;(129):5-11. Review.

PMID:
12166607
9.

Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.

Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S.

Diabetes Care. 2000 Nov;23(11):1660-5.

12.

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control.

Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, Handelsman Y, Horton ES, Lebovitz H, Levy P, Moghissi ES, Schwartz SS.

Endocr Pract. 2009 Sep-Oct;15(6):540-59. Erratum in: Endocr Pract. 2009 Nov-Dec;15(7):768-70.

PMID:
19858063
13.

The importance of postprandial glucose to treatments and outcomes in patients with type 2 diabetes.

Herman ME, Moore RS.

Manag Care Interface. 2001 Nov;14(11):63-9.

PMID:
11715766
14.

Control of post-prandial hyperglycemia--an essential part of good diabetes treatment and prevention of cardiovascular complications.

Hanefeld M, Temelkova-Kurktschiev T.

Nutr Metab Cardiovasc Dis. 2002 Apr;12(2):98-107. Review.

PMID:
12189909
15.

Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: a pooled analysis of treat-to-target trials.

Fonseca V, Davidson J, Home P, Snyder J, Jellinger P, Dyhr Toft A, Barnett A.

Curr Med Res Opin. 2010 Jul;26(7):1621-8. doi: 10.1185/03007995.2010.485087.

PMID:
20429817
16.

Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM).

Abraira C, Henderson WG, Colwell JA, Nuttall FQ, Comstock JP, Emanuele NV, Levin SR, Sawin CT, Silbert CK.

Diabetes Care. 1998 Apr;21(4):574-9.

PMID:
9571345
17.

Fasting and post-prandial glucose and diabetic complication. A meta-analysis.

Monami M, Adalsteinsson JE, Desideri CM, Ragghianti B, Dicembrini I, Mannucci E.

Nutr Metab Cardiovasc Dis. 2013 Jul;23(7):591-8. doi: 10.1016/j.numecd.2013.03.007. Epub 2013 May 24.

PMID:
23711419
18.

Integrating glycaemic variability in the glycaemic disorders of type 2 diabetes: a move towards a unified glucose tetrad concept.

Monnier L, Colette C, Owens DR.

Diabetes Metab Res Rev. 2009 Jul;25(5):393-402. doi: 10.1002/dmrr.962. Review.

PMID:
19437415
19.
20.

Insulin initiation and intensification: insights from new studies.

Kumar A, Kalra S.

J Assoc Physicians India. 2011 Apr;59 Suppl:17-22.

PMID:
21818994

Supplemental Content

Support Center